Computer Directed Photodynamic Therapy of Prostate Ca

计算机引导前列腺钙光动力治疗

• 批准号: 6633985
• 负责人: JERZY JANKUN
• 金额: $ 28.79万
• 依托单位: UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-02 至 2006-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6633985
• 关键词: computer assisted patient care; computer simulation; computer system design /evaluation; dogs; neoplasm /cancer photoradiation therapy; nonhuman therapy evaluation; photosensitizing agents; porphyrins; prostate neoplasms

DESCRIPTION (Verbatim from Applicant's Abstract): The objective of the proposal is to provide a critical body of knowledge with the ultimate goal of transferring photodynamic therapy (PDT) to the clinical arena for the treatment of prostate cancer. The widespread use of PSA test as an adjunct to digital rectal examination has led to an increase in the diagnosis of prostate cancer in its early stages. Treatment of organ confined prostatic cancer includes radical prostatectomy, radiotherapy, brachytherapy and cryosurgical ablation. Results from all these are favorable at least in terms of short outcomes. Still, with Tic disease, 30 percent of patients will have biochemical failure within 5 years of treatment. Clearly novel methods of prostate cancer treatment are needed. We want to utilize PDT as a novel approach to the treatment of prostatic cancer. PDT for prostate cancer depends on the sequestration of a PDT drug within the glandular tissue of the prostate. The photosensitizer is subsequently activated by high-energy light producing cytotoxic substances, which in turn destroy cancerous tissue. Since prostate cancer is a multi-focal disease, PDT must ablate the prostate completely. Complete ablation will depend on quantification of tissue sensitivity to a photosensitizer, precise placement of light sources in the prostate and delivery of a therapeutic light dose to the entire gland. The prostate is irregular in shape, so transurethral light delivery cannot be used for the treatment of the majority of prostate cancers. Additionally, most cancers are located in the peripheral zone of the prostate, an area unlikely to be reached by transurethrally launched light. Sources of light and their spatial distribution must be tailored to each patient. More uniform light distribution can be achieved by interstitial light irradiation. In this case, the light is delivered by diffusers placed within the substance of the prostate parallel to the urethra at a distance optimized to deliver adequate levels of light and to create the desired photodynamic effect. To achieve uniform light distribution throughout the prostate we are developing a computer program that can determine treatment effects by calculating the distribution of light energy depending on the number of light sources placed in the prostate, their position in the gland, the dimension of the prostate, and the tissue attenuation coefficient.

描述（逐字摘自申请人摘要）：提案的目标 是提供批判性的知识体系，其最终目标是 将光动力疗法（PDT）转移到临床领域进行治疗 前列腺癌。 PSA 测试作为数字化测试的辅助手段得到广泛应用 直肠检查导致前列腺癌的诊断率增加 处于早期阶段。器官局限性前列腺癌的治疗包括 根治性前列腺切除术、放射治疗、近距离放射治疗和冷冻消融术。 所有这些的结果至少就短期结果而言是有利的。 尽管如此，对于抽动症，30% 的患者会出现生化衰竭 治疗5年内。前列腺癌治疗的明显新颖方法 需要。我们希望利用 PDT 作为治疗以下疾病的新方法 前列腺癌。前列腺癌的 PDT 取决于 PDT 的隔离 前列腺腺体组织内的药物。光敏剂是 随后被高能光激活产生细胞毒性物质， 进而破坏癌组织。由于前列腺癌是多灶性的 疾病，PDT必须完全消融前列腺。完全消融取决于 量化组织对光敏剂的敏感性，精确放置 前列腺中的光源并向患者输送治疗光剂量 整个腺体。前列腺形状不规则，所以经尿道光 分娩不能用于治疗大多数前列腺癌。 此外，大多数癌症位于前列腺的周围区域， 经尿道发射的光不太可能到达的区域。来源 光线及其空间分布必须适合每个患者。更多的 通过间隙光照射可以实现均匀的光分布。 在这种情况下，光由放置在物质内的漫射器传递 前列腺与尿道平行，距离优化以输送 充足的光照水平并产生所需的光动力效果。到 在整个前列腺内实现均匀的光分布，我们正在开发一种 可以通过计算来确定治疗效果的计算机程序 光能量的分布取决于放置的光源数量 前列腺、它们在腺体中的位置、前列腺的尺寸，以及 组织衰减系数。